These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 11975880)

  • 1. [Tibolone-induced hepatotoxicity].
    Blanco Sampascual S; de Las Heras Niño B; Cabezudo Gil P; Ruiz Eguiluz P; Orive Cura V
    Gastroenterol Hepatol; 2002 Apr; 25(4):274. PubMed ID: 11975880
    [No Abstract]   [Full Text] [Related]  

  • 2. Tibolone-induced acute hepatitis: Well-known drug, little-known complication.
    Macedo G; Silva M; Vilas-Boas F; Lopes S; Peixoto A; Carneiro F
    Gastroenterol Hepatol; 2017 Apr; 40(4):298-300. PubMed ID: 27093896
    [No Abstract]   [Full Text] [Related]  

  • 3. Tibolone.
    Reynir Tomas G
    Acta Obstet Gynecol Scand; 2004 Jun; 83(6):606. PubMed ID: 15144349
    [No Abstract]   [Full Text] [Related]  

  • 4. Does tibolone exacerbate atherosclerosis?
    Clarkson TB
    Eur Heart J; 2006 Mar; 27(6):635-7. PubMed ID: 16415302
    [No Abstract]   [Full Text] [Related]  

  • 5. A case report of recurrent endometriosis following Tibolone hormone replacement therapy.
    Sundar SS; Gornall RJ; Kerr-Wilson R; Swingler GR; Kinder RB; McCarthy K
    J Obstet Gynaecol; 2007 May; 27(4):433-4. PubMed ID: 17654209
    [No Abstract]   [Full Text] [Related]  

  • 6. Endometrial adenocarcinoma after prolonged tibolone therapy.
    Nassar AH; Khalil AM; Seoud MA; Usta IM
    Int J Gynaecol Obstet; 2005 Jul; 90(1):78-9. PubMed ID: 15913616
    [No Abstract]   [Full Text] [Related]  

  • 7. Tibolone and breast cancer risk: effects of selection bias cannot be eliminated in observational studies.
    Coomarasamy A
    BJOG; 2008 Jun; 115(7):919. PubMed ID: 18485174
    [No Abstract]   [Full Text] [Related]  

  • 8. Carcinoma of the endometrium in patients treated with tibolone.
    Yazigi R; Sahid S; Contreras L; Rodriguez T
    Gynecol Oncol; 2004 May; 93(2):568-70. PubMed ID: 15099984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study.
    Langer RD; Landgren BM; Rymer J; Helmond FA;
    Am J Obstet Gynecol; 2006 Nov; 195(5):1320-7. PubMed ID: 16875644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tibolone reduces osteoporotic fracture risk and breast cancer risk, but increases the risk of stroke.
    de Melo NR; Pompei LM
    Gynecol Endocrinol; 2010 Feb; 26(2):73-5. PubMed ID: 19995151
    [No Abstract]   [Full Text] [Related]  

  • 11. By the way, doctor. What happened to tibolone--the estrogen alternative we heard about a while ago? Did it turn out not to be effective?
    Robb-Nicholson C
    Harv Womens Health Watch; 2004 Apr; 11(8):8. PubMed ID: 15100062
    [No Abstract]   [Full Text] [Related]  

  • 12. Tibolone and risk of endometrial polyps: a prospective, comparative study with hormone therapy.
    Perez-Medina T; Bajo-Arenas J; Haya J; Sanfrutos L; Iniesta S; Bueno B; Castelo-Branco C
    Menopause; 2003; 10(6):534-7. PubMed ID: 14627862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The LIBERATE tibolone trial in breast cancer survivors.
    Speroff L
    Maturitas; 2009 May; 63(1):1-3. PubMed ID: 19327923
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of fenofibrate on HDL cholesterol and HDL particle concentration in postmenopausal women on tibolone therapy.
    Stuckey BG; Barrett PH; Wagner JM; Hampton RA; Chan DC; Brown SJ; Watts GF
    Clin Endocrinol (Oxf); 2010 Oct; 73(4):497-501. PubMed ID: 20560981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What have we really learned from 'LIBERATE' trial?
    Dimitrakakis C; Tsigginou A; Keramopoulos D; Antsaklis A
    Maturitas; 2010 May; 66(1):99-100. PubMed ID: 20236777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials.
    Biglia N; Maffei S; Lello S; Nappi RE
    Gynecol Endocrinol; 2010 Nov; 26(11):804-14. PubMed ID: 20586550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose tibolone (1.25 mg/d) does not affect muscle strength in older women.
    Ribom EL; Svensson P; van Os S; Larsson M; Naessen T
    Menopause; 2011 Feb; 18(2):194-7. PubMed ID: 20689464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tibolone revisited: still a good treatment option for healthy, early postmenopausal women.
    Kenemans P
    Gynecol Endocrinol; 2010 Apr; 26(4):237-9. PubMed ID: 20017707
    [No Abstract]   [Full Text] [Related]  

  • 19. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
    Christodoulakos GE; Botsis DS; Lambrinoudaki IV; Papagianni VD; Panoulis CP; Creatsa MG; Alexandrou AP; Augoulea AD; Dendrinos SG; Creatsas GC
    Maturitas; 2006 Mar; 53(4):413-23. PubMed ID: 16140483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tibolone (Livial) enhances warfarin-induced anticoagulation in postmenopausal women.
    Elbers J; Hageluken C; Wadham A
    Maturitas; 2007 Jan; 56(1):94-100. PubMed ID: 16887301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.